ID   A-704
AC   CVCL_1065
SY   A.704; A704
DR   BTO; BTO:0004583
DR   CLO; CLO_0001546
DR   CLO; CLO_0001609
DR   CLO; CLO_0001610
DR   CLDB; cl167
DR   CLDB; cl168
DR   CLDB; cl170
DR   CLDB; cl5026
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-7911
DR   ATCC; HTB-45
DR   BioSample; SAMN03471120
DR   BioSample; SAMN03472920
DR   BioSample; SAMN10987988
DR   cancercelllines; CVCL_1065
DR   Cell_Model_Passport; SIDM00849
DR   ChEMBL-Cells; CHEMBL3307650
DR   ChEMBL-Targets; CHEMBL614567
DR   CLS; 300217
DR   Cosmic; 687938
DR   Cosmic; 910920
DR   Cosmic; 979707
DR   Cosmic; 982279
DR   Cosmic; 1995339
DR   Cosmic; 2520641
DR   Cosmic-CLP; 910920
DR   DepMap; ACH-000429
DR   ECACC; 93020513
DR   EGA; EGAS00001000978
DR   GDSC; 910920
DR   GEO; GSM374459
DR   GEO; GSM886860
DR   GEO; GSM887925
DR   GEO; GSM1669591
DR   IARC_TP53; 21169
DR   IARC_TP53; 27550
DR   ICLC; HTL95007
DR   IZSLER; BS TCL 117
DR   KCLB; 30045
DR   LiGeA; CCLE_470
DR   LINCS_LDP; LCL-1762
DR   NCI-DTP; A704
DR   PharmacoDB; A704_50_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1065
DR   PubChem_Cell_line; CVCL_1065
DR   Wikidata; Q54606061
RX   PubMed=77569;
RX   PubMed=450131;
RX   PubMed=571047;
RX   PubMed=3335022;
RX   PubMed=3518877;
RX   PubMed=4357758;
RX   PubMed=6220172;
RX   PubMed=6244232;
RX   PubMed=6256643;
RX   PubMed=6500159;
RX   PubMed=6825208;
RX   PubMed=7591954;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=22949125;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28489074;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Population: African American.
CC   HLA typing: A*01,03; B*08,12 (PubMed=77569).
CC   HLA typing: A*34:02,74:01; B*35:01,44:03; C*04:01,04:01; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*11:02,15:03 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI-low) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Asp (c.376T>G); ClinVar=VCV000265333; Zygosity=Heterozygous (Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Arg (c.403T>C); ClinVar=VCV000376560; Zygosity=Heterozygous (Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu258Ter (c.772G>T); ClinVar=VCV000486557; Zygosity=Heterozygous (Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=71.07%; Native American=0%; East Asian, North=6.26%; East Asian, South=0%; South Asian=0%; European, North=2.53%; European, South=20.13% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-7911; true.
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
CC   Cell type: Epithelial cell of kidney; CL=CL_0002518.
ST   Source(s): ATCC; CLS; Cosmic-CLP; ECACC; IZSLER; KCLB; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 7,8
ST   D13S317: 8
ST   D16S539: 12,13
ST   D18S51: 16,17
ST   D19S433: 13
ST   D21S11: 28,32
ST   D2S1338: 16,21
ST   D3S1358: 15
ST   D5S818: 10,11
ST   D7S820: 10
ST   D8S1179: 13,15
ST   FGA: 22,23
ST   Penta D: 2.2,11
ST   Penta E: 8,17
ST   TH01: 7 (PubMed=25877200)
ST   TH01: 7,9 (ATCC; CLS; Cosmic-CLP; ECACC; IZSLER; KCLB)
ST   TPOX: 11
ST   vWA: 14,18
DI   NCIt; C9385; Renal cell carcinoma
DI   ORDO; Orphanet_217071; Renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   78Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 39
//
RX   PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x;
RA   Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A.;
RT   "Tissue typing of cells in culture. III. HLA antigens of established
RT   human cell lines. Attempts at typing by the mixed hemadsorption
RT   technique.";
RL   Tissue Antigens 11:279-286(1978).
//
RX   PubMed=450131; DOI=10.1038/279797a0;
RA   Day R.S. III, Ziolkowski C.H.J.;
RT   "Human brain tumour cell strains with deficient host-cell reactivation
RT   of N-methyl-N'-nitro-N-nitrosoguanidine-damaged adenovirus 5.";
RL   Nature 279:797-799(1979).
//
RX   PubMed=571047;
RA   Fogh J.;
RT   "Cultivation, characterization, and identification of human tumor
RT   cells with emphasis on kidney, testis, and bladder tumors.";
RL   Natl. Cancer Inst. Monogr. 49:5-9(1978).
//
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=4357758; DOI=10.1093/jnci/51.5.1417;
RA   Giard D.J., Aaronson S.A., Todaro G.J., Arnstein P., Kersey J.H.,
RA   Dosik H., Parks W.P.;
RT   "In vitro cultivation of human tumors: establishment of cell lines
RT   derived from a series of solid tumors.";
RL   J. Natl. Cancer Inst. 51:1417-1423(1973).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=6244232;
RA   Williams R.D.;
RT   "Human urologic cancer cell lines.";
RL   Invest. Urol. 17:359-363(1980).
//
RX   PubMed=6256643; DOI=10.1038/288724a0;
RA   Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A.,
RA   Lubiniecki A.S., Girardi A.J., Galloway S.M., Bynum G.D.;
RT   "Defective repair of alkylated DNA by human tumour and
RT   SV40-transformed human cell strains.";
RL   Nature 288:724-727(1980).
//
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
//
RX   PubMed=6825208; DOI=10.1093/carcin/4.2.199;
RA   Yarosh D.B., Foote R.S., Mitra S., Day R.S. III;
RT   "Repair of O6-methylguanine in DNA by demethylation is lacking in Mer-
RT   human tumor cell strains.";
RL   Carcinogenesis 4:199-205(1983).
//
RX   PubMed=7591954; DOI=10.1111/j.1349-7006.1995.tb03087.x;
RA   Kinoshita H., Yamada H., Ogawa O., Kakehi Y., Osaka M., Nakamura E.,
RA   Mishina M., Habuchi T., Takahashi R., Sugiyama T., Yoshida O.;
RT   "Contribution of chromosome 9p21-22 deletion to the progression of
RT   human renal cell carcinoma.";
RL   Jpn. J. Cancer Res. 86:795-799(1995).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22949125; DOI=10.1002/ijc.27822;
RA   Pawlowski R., Muhl S.M., Sulser T., Krek W., Moch H., Schraml P.;
RT   "Loss of PBRM1 expression is associated with renal cell carcinoma
RT   progression.";
RL   Int. J. Cancer 132:E11-E17(2013).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28489074; DOI=10.1038/ncomms15165;
RA   Sinha R., Winer A.G., Chevinsky M., Jakubowski C., Chen Y.-B., Dong Y.-Y.,
RA   Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C.,
RA   Hsieh J.J.-D., Hakimi A.A.;
RT   "Analysis of renal cancer cell lines from two major resources enables
RT   genomics-guided cell line selection.";
RL   Nat. Commun. 8:15165.1-15165.10(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//